Globus Medical's stock surged 9.20% in pre-market trading following the release of its first-quarter 2026 financial results, which significantly exceeded analyst expectations.

The musculoskeletal technology company reported adjusted earnings per share of $1.12, beating the consensus estimate of $0.92, and revenue of $759.85 million, surpassing the $737.00 million estimate. This represents a 27% year-over-year revenue increase.

Management attributed the strong performance to organic growth exceeding 13%, driven by market share gains and procedural volume strength in its core spine business. The company also raised its full-year 2026 non-GAAP diluted EPS guidance to $4.70-$4.80 from the previous range of $4.40-$4.50 while reaffirming its revenue outlook of $3.18-$3.22 billion.